Zumanix Remedies Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 04-07-2024
- Paid Up Capital ₹ 0.11 M
as on 04-07-2024
- Company Age 11 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 11.01%
(FY 2022)
- Profit 14.24%
(FY 2022)
- Ebitda 14.74%
(FY 2022)
- Net Worth 28.19%
(FY 2022)
- Total Assets 11.03%
(FY 2022)
About Zumanix Remedies
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.11 M, as per Ministry of Corporate Affairs (MCA) records.
Shruti Agrawal, Akriti Agarwal, Vikash Agrawal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232CT2013PTC000847
- Company No.
000847
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 May 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chhattisgarh
Industry
Company Details
- Location
Raipur, Chattisgarh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Zumanix Remedies?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikash Agrawal  | Managing Director | 09-May-2013 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Utkarsh Bhawsinka | Director | 03-May-2022 | Current |
| Shruti Agrawal | Director | 26-Mar-2015 | Current |
| Akriti Agarwal | Director | 26-Mar-2015 | Current |
Financial Performance of Zumanix Remedies.
Zumanix Remedies Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 11.01% increase. The company also saw a substantial improvement in profitability, with a 14.24% increase in profit. The company's net worth Soared by an impressive increase of 28.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zumanix Remedies?
In 2021, Zumanix Remedies had a promoter holding of 38.10% and a public holding of 61.90%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Cartel Lifescience Private LimitedActive 4 years 2 monthsAkriti Agarwal, Vikash Agrawal and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zumanix Remedies?
Unlock and access historical data on people associated with Zumanix Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zumanix Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zumanix Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
